Latest news with #EUR1.1
Yahoo
14-05-2025
- Business
- Yahoo
Munchener Ruckversicherungs-Gesellschaft AG (MURGF) Q1 2025 Earnings Call Highlights: Resilient ...
Net Earnings: EUR1.1 billion. Running Yield: 3.5%. Return on Investment (ROI): 2.2% overall; 1.7% at ERGO, 2.9% in reinsurance. Currency Losses: EUR500 million due to US dollar devaluation. Reinvestment Yield: Increased to 4.6%. Life and Health Technical Result: EUR608 million. LA Wildfire Losses: EUR1.1 billion total; EUR0.8 billion in P&C reinsurance. Combined Ratio: 83.9% with a discount benefit of around 10%. April Renewals Premium Expansion: More than 6%. Price Decline: 2.5% overall; 1.7% excluding business mix effects. Global Specialty Insurance Net Result: EUR182 million in 2024. ERGO Net Result: EUR241 million. ERGO Germany Segment Result: EUR140 million. ERGO International Business Net Result: EUR100 million. Solvency II Ratio: 285%. 2025 Net Result Outlook: About EUR6 billion. Warning! GuruFocus has detected 6 Warning Sign with MURGF. Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Munchener Ruckversicherungs-Gesellschaft AG (MURGF) reported a resilient Q1 result with net earnings of EUR1.1 billion, demonstrating strong diversification of earnings drivers. The life and health total technical result significantly exceeded expectations, driven by positive experience in the US portfolio. The reinvestment yield increased to 4.6%, providing further support for an uptrend in the running yield. ERGO delivered a pleasing net result of EUR241 million, slightly ahead of expectations, with strong performance in Life and Health segments. The Solvency II ratio remained stable at 285%, reflecting a strong economic position despite a EUR2 billion share buyback. High large losses, fair value changes in investment results, and significant currency movements negatively impacted net earnings. The ROI was burdened by negative fair value changes of fixed income instruments, particularly affecting ERGO with an ROI of 1.7%. Currency losses amounted to around EUR500 million due to the devaluation of the US dollar. The combined ratio for Global Specialty Insurance (GSI) was elevated at 95.5% due to major losses, including LA wildfire claims. The business mix effects and an increase in the loss component negatively impacted the basic loss ratio. Q: Can you provide an outlook for the midyear renewals and your approach to volume versus margin? A: Christoph Jurecka, CFO, explained that while it's early days, the market remains attractive with less than a 1% price decline so far. The company prioritizes client relationships and profitability, and decisions are made based on discussions with clients rather than a top-down approach. Q: How do you view the use of reserving buffers in a softening cycle? A: Christoph Jurecka emphasized that while buffers are available for volatility, they are not intended to support earnings in a prolonged soft market. The focus remains on maintaining profitability without relying on reserves for cross-subsidization. Q: Can you explain the experience variance in Life Re's Q1 results? A: The positive experience variance was driven by favorable developments in US mortality, disability, and LTC, along with fewer large losses. However, Christoph Jurecka cautioned that this is not expected to be a recurring trend. Q: How did the Solvency II ratio remain stable despite the share buyback? A: The Solvency II ratio remained stable due to strong operating performance and significant new business in life and health, which increased own funds. The methodology does not include a dividend accrual, allowing the company to offset the EUR2 billion share buyback. Q: What is the plan to achieve the 90% combined ratio target for Global Specialty Insurance (GSI)? A: The 90% target is based on IFRS numbers without internal reinsurance. While large losses have impacted results, the underlying profitability aligns with the target. The company is focused on profitability and implementing pricing and underwriting actions. Q: What is your appetite for US long-term care (LTC) business? A: Christoph Jurecka stated that the company's appetite for LTC is generally low, with a preference for mortality business. The large transactions in the quarter did not include LTC. Q: How do you view the FX headwind and its impact on revenue growth targets? A: The FX headwind has made growth targets more challenging, but it's too early to revise them. The company actively manages its US dollar position and reduced its long position in Q1. Q: Can you comment on the potential impact of US tax changes on remittances? A: Christoph Jurecka expressed concerns about the global minimum taxation and potential US retaliatory measures. The company is flexible in its business operations and can adapt to mitigate potential impacts. Q: How do you view the current pricing level in historical context? A: The current pricing level remains very attractive, with less than a 1% decline from a historically high level. The market is still far from a soft market, indicating early signs of softening from an extremely hard market. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Munchener Ruckversicherungs-Gesellschaft AG (MURGF) Q1 2025 Earnings Call Highlights: Resilient ...
Net Earnings: EUR1.1 billion. Running Yield: 3.5%. Return on Investment (ROI): 2.2% overall; 1.7% at ERGO, 2.9% in reinsurance. Currency Losses: EUR500 million due to US dollar devaluation. Reinvestment Yield: Increased to 4.6%. Life and Health Technical Result: EUR608 million. LA Wildfire Losses: EUR1.1 billion total; EUR0.8 billion in P&C reinsurance. Combined Ratio: 83.9% with a discount benefit of around 10%. April Renewals Premium Expansion: More than 6%. Price Decline: 2.5% overall; 1.7% excluding business mix effects. Global Specialty Insurance Net Result: EUR182 million in 2024. ERGO Net Result: EUR241 million. ERGO Germany Segment Result: EUR140 million. ERGO International Business Net Result: EUR100 million. Solvency II Ratio: 285%. 2025 Net Result Outlook: About EUR6 billion. Warning! GuruFocus has detected 6 Warning Sign with MURGF. Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Munchener Ruckversicherungs-Gesellschaft AG (MURGF) reported a resilient Q1 result with net earnings of EUR1.1 billion, demonstrating strong diversification of earnings drivers. The life and health total technical result significantly exceeded expectations, driven by positive experience in the US portfolio. The reinvestment yield increased to 4.6%, providing further support for an uptrend in the running yield. ERGO delivered a pleasing net result of EUR241 million, slightly ahead of expectations, with strong performance in Life and Health segments. The Solvency II ratio remained stable at 285%, reflecting a strong economic position despite a EUR2 billion share buyback. High large losses, fair value changes in investment results, and significant currency movements negatively impacted net earnings. The ROI was burdened by negative fair value changes of fixed income instruments, particularly affecting ERGO with an ROI of 1.7%. Currency losses amounted to around EUR500 million due to the devaluation of the US dollar. The combined ratio for Global Specialty Insurance (GSI) was elevated at 95.5% due to major losses, including LA wildfire claims. The business mix effects and an increase in the loss component negatively impacted the basic loss ratio. Q: Can you provide an outlook for the midyear renewals and your approach to volume versus margin? A: Christoph Jurecka, CFO, explained that while it's early days, the market remains attractive with less than a 1% price decline so far. The company prioritizes client relationships and profitability, and decisions are made based on discussions with clients rather than a top-down approach. Q: How do you view the use of reserving buffers in a softening cycle? A: Christoph Jurecka emphasized that while buffers are available for volatility, they are not intended to support earnings in a prolonged soft market. The focus remains on maintaining profitability without relying on reserves for cross-subsidization. Q: Can you explain the experience variance in Life Re's Q1 results? A: The positive experience variance was driven by favorable developments in US mortality, disability, and LTC, along with fewer large losses. However, Christoph Jurecka cautioned that this is not expected to be a recurring trend. Q: How did the Solvency II ratio remain stable despite the share buyback? A: The Solvency II ratio remained stable due to strong operating performance and significant new business in life and health, which increased own funds. The methodology does not include a dividend accrual, allowing the company to offset the EUR2 billion share buyback. Q: What is the plan to achieve the 90% combined ratio target for Global Specialty Insurance (GSI)? A: The 90% target is based on IFRS numbers without internal reinsurance. While large losses have impacted results, the underlying profitability aligns with the target. The company is focused on profitability and implementing pricing and underwriting actions. Q: What is your appetite for US long-term care (LTC) business? A: Christoph Jurecka stated that the company's appetite for LTC is generally low, with a preference for mortality business. The large transactions in the quarter did not include LTC. Q: How do you view the FX headwind and its impact on revenue growth targets? A: The FX headwind has made growth targets more challenging, but it's too early to revise them. The company actively manages its US dollar position and reduced its long position in Q1. Q: Can you comment on the potential impact of US tax changes on remittances? A: Christoph Jurecka expressed concerns about the global minimum taxation and potential US retaliatory measures. The company is flexible in its business operations and can adapt to mitigate potential impacts. Q: How do you view the current pricing level in historical context? A: The current pricing level remains very attractive, with less than a 1% decline from a historically high level. The market is still far from a soft market, indicating early signs of softening from an extremely hard market. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-02-2025
- Business
- Yahoo
Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...
Total Sales Growth: 9.9% at constant exchange rates, exceeding EUR3.4 billion. Core Operating Margin: 32.6%. Core Operating Income: EUR1.1 billion, a growth of 10.8%. Free Cash Flow: EUR774 million, an increase of 8.9%. Revenue from Ex-Somatuline Portfolio: Grew by 12.2%. Cabometyx Sales: Increased by 13.3% for the full year. ONIVYDE Sales: Grew 23.7% for the full year. Fidrisertib Sales: Rose by 24%. Dysport Sales Growth: 9.2% for the full year. Bylvay Sales: EUR136 million. IQIRVO Sales: EUR22 million. R&D Costs: Increased by 10.9%, exceeding 20% of sales. SG&A Costs: Increased by 3.3%, with a ratio to sales at 34.4%. Net Cash Position: EUR160 million at the end of December. Dividend Increase: From EUR1.2 to EUR1.4 per share. Warning! GuruFocus has detected 4 Warning Signs with IPSEF. Release Date: February 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Ipsen SA (IPSEF) reported a 9.9% increase in total sales for 2024, driven by strong performance in their ex-somatuline portfolio. The company achieved a core operating margin of 32.6%, reflecting efficient cost management and strong sales performance. Ipsen SA (IPSEF) received a positive FDA decision for ONIVYDE in first-line pancreatic ductal adenocarcinoma, with subsequent approvals in the US and EU. The company anticipates significant pipeline milestones in 2025, including potential approvals for Cabometyx in neuroendocrine tumors and Tovorafenib in Europe. Ipsen SA (IPSEF) has a strong balance sheet with no debt and EUR 2.3 billion available for external innovation, indicating financial stability and capacity for growth. Ipsen SA (IPSEF) faces increased competition and pricing pressure for Cabometyx in Europe and China, impacting sales growth. The company recognized an impairment loss of EUR 281 million related to Sohonos due to lower-than-anticipated patient uptake. Somatuline is expected to face accelerated erosion due to increased generic competition, impacting profitability. The aesthetics market in the US is experiencing some softening, which could affect future growth prospects for Dysport. Ipsen SA (IPSEF) anticipates a contraction in core operating profit margin in 2025 due to increased R&D expenses and competitive pressures. Q: Could you provide more details on the expected erosion pattern for Somatuline in 2025 and the current state of generic competition in Europe and the US? A: David Loew, CEO: The erosion pattern for Somatuline is expected to accelerate compared to historical levels due to anticipated market entry by additional generics, likely around mid-year. In Europe and the US, we have seen significant shortages from existing generics, but we expect increased competition and accelerated erosion moving forward. Q: Can you explain the drivers behind the expected margin contraction in 2025 and how it will phase between H1 and H2? A: Aymeric le Chatelier, CFO: The margin contraction is primarily due to increased erosion from Somatuline and continued investment in R&D and SG&A to support ongoing and future launches. H1 margins will be higher due to lower costs and less impact from generics, while H2 will see more erosion and investment, leading to lower margins. Q: How is the launch of IQIRVO progressing, and what are the competitive dynamics in the market? A: David Loew, CEO: The IQIRVO launch is progressing well, with most patients being de novo second-line. We are seeing good feedback from prescribers despite competition from Gilead. We have increased our field force and presented new data on fatigue, which affects 80% of PBC patients. Q: What is the current market share for ONIVYDE in first-line pancreatic cancer, and what is the potential for growth in the community setting? A: David Loew, CEO: ONIVYDE is used by 32% of large academic centers, with growth primarily from the first-line setting. The patient flow is about 50-50 between academic and community settings, indicating significant potential for growth in community practices. Q: What are your expectations for the growth trajectory of IQIRVO in 2025, and how does it compare to Gilead's product? A: David Loew, CEO: We anticipate market expansion and are sticking to our peak sales guidance for IQIRVO. While we can't comment on Gilead's trajectory, we are pleased with our current uptake and expect continued growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
06-02-2025
- Business
- Yahoo
Vestas Wind Systems AS (VWDRY) Q4 2024 Earnings Call Highlights: Record Order Intake and Strong ...
Revenue: EUR17.3 billion for the full year 2024, a 12% increase year on year. EBIT Margin: 4.3% for the full year 2024. Service EBIT: EUR448 million for the full year 2024. Order Intake: 17 gigawatts, valued at EUR19 billion. Dividend Proposal: EUR0.55 per share. Share Buyback: EUR100 million initiated. Q4 Revenue Growth: 29% year on year. Q4 Gross Margin: 18.1%, an improvement of over 7 percentage points. Q4 EBIT Margin: 12.4%. Power Solutions Q4 EBIT Margin: 12.9%. Service Revenue Growth: 30% year on year in Q4. Operating Cash Flow: EUR2.2 billion in Q4. Adjusted Free Cash Flow: EUR1.1 billion for the full year 2024. Net Cash Position: Over EUR800 million at year-end 2024. Order Backlog: EUR31.6 billion for Power Solutions; EUR37 billion for Service. 2025 Revenue Outlook: EUR18 billion to EUR20 billion. 2025 EBIT Margin Outlook: 4% to 7%. 2025 Service EBIT Outlook: Around EUR700 million. 2025 Investment Level: EUR1.2 billion. Warning! GuruFocus has detected 9 Warning Signs with VWDRY. Release Date: February 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Vestas Wind Systems AS (VWDRY) achieved a record order intake of 17 gigawatts, valued at EUR19 billion, marking a high ASP and strong momentum in both onshore and offshore sectors. The company ended 2024 with a revenue of EUR17.3 billion and an EBIT margin of 4.3%, meeting its outlook for the year. Vestas proposed a dividend of EUR0.55 per share and announced a share buyback of EUR100 million, reflecting confidence in its financial position. The service order backlog grew to nearly EUR37 billion, solidifying Vestas' position as the largest service business in the industry. Vestas reported a strong Q4 with a 29% year-on-year revenue increase, driven by higher revenue in both Power Solutions and Service segments, and achieved a 12.4% EBIT margin in Q4. Rising costs posed challenges for the service segment in 2024, necessitating a recovery plan to address operational inefficiencies and quality-related effects. The offshore ramp-up is expected to be margin dilutive in 2025, with significant investments required for manufacturing and amortization. The geopolitical and trade volatility, along with ongoing inflation, presents uncertainties that could impact future operations and profitability. The company faced five fatalities in 2024, highlighting ongoing safety challenges that need to be addressed. Vestas' long-term ambition of achieving a 25% EBIT margin in the service segment remains unmet, with current margins at 18%. Q: Could you help us understand the 2025 EBIT margin guidance and how offshore impacts it? A: Offshore is a significant investment affecting the margin due to depreciation and amortization. The onshore and service segments are strong, and you can estimate the offshore investment based on the onshore and service performance. Q: Given the political situation in the US, should we expect any US orders soon? A: The US market is dynamic, with onshore and offshore segments behaving differently. Offshore has slowed, but onshore has a strong backlog for 2025 and 2026. We expect continued orders, possibly even in Q1. Q: Why resume dividends and share buybacks amid offshore ramp-up and US uncertainties? A: We are confident in our 2025 and 2026 outlooks and backlog. The decision reflects our strong cash position and commitment to shareholders, despite the challenges of ramping up offshore production. Q: How does the levelized cost of electricity (LCOE) impact your pricing and customer expectations? A: LCOE varies globally, but wind remains competitive. While prices have stabilized, we focus on optimizing projects to maintain viability for customers, acknowledging that LCOE can't decrease indefinitely. Q: Can you elaborate on the service business recovery plan and net contract assets? A: The recovery plan addresses cost challenges and operational inefficiencies. While net contract assets may fluctuate, we are confident in the business's health after a thorough review. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
